Drug research

ATH-1017

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
ATH-1017 for Treatment of Mild to Moderate Alzheimer's DiseaseNCT04488419	LeonaBio	Phase 2, Phase 3	Completed	2024-07-15Actual
Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's DiseaseNCT04886063	LeonaBio	Phase 2, Phase 3	Terminated	2024-10-23Actual
A Study of ATH-1017 in Mild to Moderate Alzheimer's DiseaseNCT04491006	LeonaBio	Phase 2	Completed	2022-05-20Actual
ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)NCT04831281	LeonaBio	Phase 2	Terminated	2023-04-19Actual

LeonaBioCompletedPrimary completion: 2024-07-15 · Actual

Trial details

LeonaBioTerminatedPrimary completion: 2024-10-23 · Actual

Trial details

LeonaBioCompletedPrimary completion: 2022-05-20 · Actual

Trial details

LeonaBioTerminatedPrimary completion: 2023-04-19 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.